DMD THERAPEUTICS
DMD Therapeutics Inc. operates as a biotechnology company. The company was incorporated in 2015 and is based in Seattle, Washington.
DMD THERAPEUTICS
Industry:
Biotechnology Health Care Therapeutics
Founded:
2016-01-01
Address:
Seattle, Washington, United States
Country:
United States
Total Employee:
1+
Status:
Active
Total Funding:
400 K USD
Similar Organizations
Acrivon Therapeutics
Acrivon Therapeutics is a precision oncology therapeutics company specializing in drug development through early clinical treatment success.
Chimeron Bio
Chimeron Bio develops agents for personalized cancer gene therapy.
Current Employees Featured
Founder
Investors List
Michael’s Cause
Michael’s Cause investment in Seed Round - DMD Therapeutics
Ryan’s Quest
Ryan’s Quest investment in Seed Round - DMD Therapeutics
Pietro’s Fight
Pietro’s Fight investment in Seed Round - DMD Therapeutics
More informations about "DMD Therapeutics"
5 DMD Candidates to Watch in 2025 - BioSpace
Jan 27, 2025 A nonprofit venture organization, CureDuchenne invests in many of the biotech companies working in this space, including Sarepta, Avidity …See details»
Duchenne muscular dystrophy: Five trials to watch
Mar 26, 2025 Duchenne muscular dystrophy: Five trials to watch Amid readouts from the Muscular Dystrophy Association’s annual meeting, the Clinical Trials Arena evaluates five DMD trials to keep an eye on in 2025.See details»
DMD Therapeutics - Crunchbase Company Profile & Funding
DMD Therapeutics intends to use the funds to move DMD-813 into drug development for the treatment of Duchenne Muscular Dystrophy.See details»
A Non-Profit Works to Advance a DMD Gene Therapy
Nov 21, 2024 Genethon, the non-profit gene therapy developer created by the patient association AFM-Telethon, began working with Sarepta Therapeutics in 2017 to develop a …See details»
Therapeutic approaches for Duchenne muscular dystrophy
Aug 31, 2023 Duchenne muscular dystrophy (DMD) is a monogenic muscle-wasting disorder and a priority candidate for molecular and cellular therapeutics.See details»
Simply Stated: Emerging Therapies to Treat DMD
Dec 20, 2024 New therapeutics on the horizon also provide hope for people living with DMD. Research efforts to restore or replace dystrophin have taken center stage; these therapies …See details»
FDA Approves First Gene Therapy for Treatment of Certain …
FDA Approves Elevidys, a gene therapy for the treatment of pediatric patients 4 through 5 years of age with Duchenne muscular dystrophy (DMD) with a confirmed mutation in the DMD gene …See details»
Simply Stated: Therapeutic Strategies to Treat DMD
Nov 26, 2024 Various strategies are being investigated, preclinically and clinically, in the effort to develop new therapeutics for DMD. Research advances and the promise of better therapeutics on the horizon offer hope for people …See details»
Capricor files cell therapy for DMD cardiomyopathy …
Jan 3, 2025 Capricor Therapeutics has completed its US marketing application for deramiocel, a cell therapy the US biotech hopes will become the first approved treatment for cardiomyopathy associated with ...See details»
Sarepta Therapeutics Provides Update on ELEVIDYS
6 days ago The DMD indication in non-ambulatory patients is approved under accelerated approval based on expression of ELEVIDYS micro-dystrophin (noted hereafter as “micro-dystrophin”) in skeletal muscle. Continued approval for this …See details»
Muscular Dystrophy Association Celebrates FDA …
The FDA approval of the first gene therapy for Duchenne Muscular Dystrophy (DMD) by Sarepta Therapeutics is ground-breaking and designed to target the underlying cause of the disease. The Muscular Dystrophy Association (MDA) …See details»
Can Solid Biosciences Challenge Sarepta in the DMD Market?
2 days ago That is where Solid Biosciences steps in. In mid-February, Solid shared clinical data on its DMD treatment, SGT-003. The results for efficacy and safety were impressive.See details»
NCATS Enables a Drug’s Path to FDA Approval for Duchenne …
DMD is a rare, inherited, often devastating disease that weakens muscles. More than a decade ago, a Rockville, MD-based company, ReveraGen BioPharma Inc., approached NCATS’ …See details»
CRISPR Therapeutics for Duchenne Muscular Dystrophy - PMC
Duchenne muscular dystrophy (DMD) is an X-linked recessive neuromuscular disorder with a prevalence of approximately 1 in 3500–5000 males. DMD manifests as childhood-onset …See details»
Capricor Therapeutics Announces FDA Acceptance and Priority …
The FDA grants Priority Review to applications for medicines that, if approved, provide significant improvements in the safety or effectiveness of the treatment of a serious condition. Deramiocel …See details»
Potential therapeutic for Duchenne muscular dystrophy takes step ...
Mar 12, 2025 A drug with connections to Vanderbilt University Medical Center improved heart function in patients with Duchenne muscular dystrophy (DMD), the company Cumberland …See details»
The FDA and Gene Therapy for Duchenne Muscular Dystrophy
Duchenne muscular dystrophy is a fatal, X-linked neuromuscular disease that results in progressive loss of muscle function. It is caused by alterations in the dystrophin gene (DMD) …See details»
Evolving Therapeutic Options for the Treatment of Duchenne …
Sep 6, 2023 Duchenne muscular dystrophy (DMD) is the most common childhood form of muscular dystrophy. It is caused by mutations in the DMD gene, leading to reduced or absent …See details»
Keros Therapeutics Announces Initial Topline Results from the …
The National Organization for Rare Disorders estimates that approximately one in every 3,500 male births is affected by DMD worldwide. About Keros Therapeutics, Inc.See details»
CRISPR technologies for the treatment of Duchenne muscular …
Duchenne muscular dystrophy (DMD) is a neuromuscular disease caused by mutations in the DMD gene. This review summarizes various therapeutic strategies that use CRISPR-Cas to …See details»